×
About 10,350 results

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00019539

Jun 19th, 2013 - OBJECTIVES: I. Determine the effect of monoclonal antibody VEGF on time to progression, angiogenesis, and overall survival in patients with unresectable advanced renal cell cancer. II. Evaluate serum antibody levels and biologically active vascular endothelial growth factor levels in the plasma of patients treated with this regimen. III. Evaluate the toxicity of this regimen in these patients. ...

FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
https://clinicaltrials.gov/ct2/show/NCT00098527

Jul 1st, 2013 - PRIMARY OBJECTIVES: I. Determine the radiographic response rate (complete response and partial response) in patients with refractory adenocarcinoma of the stomach or gastroesophageal junction treated with FR901228 (depsipeptide). SECONDARY OBJECTIVES: I. Determine the median time to progression and progression-free survival of patients treated with this drug. II. Determine the grade 3 and 4 tox...

Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (...
https://clinicaltrials.gov/ct2/show/NCT03222076

Jul 30th, 2018 - Objectives: Primary Objective: 1. To evaluate the safety and tolerability of therapy with nivolumab alone or nivolumab + ipilimumab in resectable HCC in the context of presurgical therapy; to evaluate the safety and tolerability of therapy with nivolumab + ipilimumab in potentially resectable HCC in the context of pre-biopsy therapy. Secondary Objectives: To assess the efficacy of presurgical n...

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00018941

Jun 16th, 2013 - OBJECTIVES: I. Determine the response rate and overall survival of patients with metastatic renal cell carcinoma treated with either low-dose or high-dose intravenous interleukin-2 (IL-2) or subcutaneous IL-2. II. Compare the toxic effects of these 3 regimens in this patient population. OUTLINE: This is a randomized study. Patients are stratified according to presence of renal tumor (yes vs no)...

Breast MRI as a Preoperative Tool for DCIS
https://clinicaltrials.gov/ct2/show/NCT00605982

Nov 5th, 2017 - Breast MRI is a fairly new technology, but it has been well studied. It is now used routinely in many patients with breast cancer. It has been shown to be useful in detecting areas of cancer that cannot be seen using other types of scans or tests. The purpose of this study is to see how often MRI can find other areas of cancer in women with one area of breast cancer, and to determine how having...

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
https://clinicaltrials.gov/ct2/show/NCT00049322

Mar 14th, 2016 - OBJECTIVES: Compare neovessel formation at 8 and 14 weeks after hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma treated with bevacizumab versus no bevacizumab (observation after chemoembolization only). Compare time to progression, objective response rate, and tumor marker progression in patients treated with these regimens. Determine the pharmacokineti...

MRI of the Liver With Eovist
https://clinicaltrials.gov/ct2/show/NCT01215838

Oct 13th, 2013 - Hepatocellular carcinoma (HCC), a form of liver cancer, is the seventh most common cause of cancer mortality in the US. The incidence rate of HCC is increasing along with the incidence of Hepatitis B and C which are known to promote HCC. Patients have a better prognosis (survival outlook) if HCC is found and treated at an early stage. MRI is the best imaging modality for diagnosing HCC. This st...

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00061178

Oct 18th, 2016 - The purpose of this study is to determine whether rhuMAb VEGF (Bevacizumab) is safe and effective for the treatment of renal cell cancer when other treatments have failed.

S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT00087412

Feb 27th, 2013 - PRIMARY OBJECTIVES: I. To assess survival in patients with advanced non-small cell lung carcinoma with a Zubrod Performance Status of 2 treated with OSI-774. II. To evaluate the objective tumor response rates (confirmed plus unconfirmed, complete and partial), in patients with advanced non-small cell lung carcinoma with a Zubrod Performance Status of 2 treated with OSI-774. III. To investigate ...

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
https://clinicaltrials.gov/ct2/show/NCT00091182

Jun 4th, 2013 - OBJECTIVES: I. Determine the response rate in children with recurrent or refractory solid tumors treated with oxaliplatin. II. Determine the cumulative toxicity of this drug in these patients. III. Determine the pharmacokinetic profile of this drug in these patients. IV. Determine time to progression and overall survival of patients treated with this drug. V. Correlate the extent of oxaliplatin...

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02584829

Nov 13th, 2017 - PRIMARY OBJECTIVES: I. Assess and compare the safety and potential toxicities associated with treating patients with metastatic Merkel cell carcinoma (MCC) with either major histocompatibility complex (MHC) up regulation and programmed cell death 1 (PD1)-axis blockade (Group 1), or MHC up-regulation, PD1-axis blockade and adoptive transfer of Merkel cell polyoma virus (MCPyV) T antigen (TAg)-sp...

Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00403169

Apr 19th, 2017 - OBJECTIVES: Evaluate the best response in patients with advanced or unresectable renal cell carcinoma (RCC) treated with lenalidomide. Evaluate the response duration, time to tumor progression, and survival of patients with advanced RCC treated with lenalidomide. Evaluate the safety of this drug in these patients. OUTLINE: This is an open-label study. Patients receive oral lenalidomide daily on...

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT02427841

Aug 30th, 2018 - PRIMARY OBJECTIVES: I. To determine the R0 (complete resection) resection rate for subjects with borderline resectable or lymph node positive pancreatic adenocarcinoma treated with a multimodality neoadjuvant therapy of preoperative gemcitabine (gemcitabine hydrochloride) and ABRAXANE (nab-paclitaxel) followed by 5-fluorouracil (fluorouracil) based image-guided intensity-modulated radiation the...

PS-341 in Treating Patients With Metastatic Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00025376

Sep 4th, 2013 - OBJECTIVES: Determine the objective response rate in patients with metastatic renal cell cancer treated with bortezomib. Determine the time to tumor progression and 1-year survival of patients treated with this drug. Determine the toxicity profile of this drug in these patients. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients r...

Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional Therapy
https://clinicaltrials.gov/ct2/show/NCT01281683

Hepatocellular carcinoma (HCC) is a major health problem worldwide. For patients with intermediate-stage disease, i.e., large or multifocal HCC without vascular invasion or extrahepatic spread, transarterial chemoembolization (TACE) is recommended as first line therapy with survival advantages. TACE can be performed repeatedly in patients with recurrent tumors who have adequate liver function r...

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT01362790

Background: Malignant mesothelioma is a form of cancer that develops on the protective lining that covers the body s internal organs. It most often occurs on the lining of the lungs and chest wall or the lining of the abdomen. There is no known cure for malignant mesothelioma, so researchers are searching for new ways to treat it. Mesothelin is a protein that is found in mesothelioma and other ...

A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02482909

Jun 25th, 2015 - The purpose of this prospective randomized study is to compare the efficacy and safety of radiofrequency ablation and hepatic resection for small hepatocellular carcinomas with very homogeneous underlying conditions.

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT02482454

Jul 31st, 2017 - The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cholangiocarcinoma.

The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT01380392

A cross-sectional correlated design will be used and (2) patients will be recruited by purposive sampling from wards and outpatient departments at a medical center in Taipei.

Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00448149

Mar 16th, 2016 - Despite significant progress in understanding the biology of renal cell carcinoma (RCC), it is estimated that over 35, 000 people in the United States will be diagnosed and approximately 12, 000 have died from this disease in 2005. Renal cell carcinoma presently ranks tenth as the leading cause of cancer death and constitutes 3% of all solid neoplasms. In contrast to many other malignancies, tr...